Agilent Technologies, Inc.

A • Medical - Diagnostics & Research

$150.84

▲ +0.86 (+0.57%)

Precio actual

ResultadosÚltimo reporte: 31 jul 2026

PERFIL FAVORABLEAtractivaConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$42.69B

Crecimiento

1.2%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 18.8%Flujo de caja libre positivo · 4.07Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.5Liquidez saludable · 1.96

Datos financieros hasta: 31 jul 2026, 12:00 a.m. UTCÚltima actualización de earnings: 31 jul 2026, 12:00 a.m. UTCÚltima actualización del perfil: 28 ago 2026, 12:06 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$150.84

Change0.57%

Shares Out283.00M

Market Cap$42.69B

Enterprise Value$44.88B

52W Range108.35 - 163.75

Beta1.23

P/E29.64

P/S5.79

P/B5.80

P/FCF28.16

EV/Sales6.09

Price$150.84

Change0.57%

Shares Out283.00M

Market Cap$42.69B

Enterprise Value$44.88B

52W Range108.35 - 163.75

Beta1.23

P/E29.64

P/S5.79

P/B5.80

P/FCF28.16

EV/Sales6.09

EV/EBITDA24.03

EV/FCF29.60

Earnings Yield3.37%

FCF Yield3.55%

Dividend Yield0.50%

Gross Margin52.43%

Oper. Margin21.29%

Profit Margin18.75%

Debt/Eq0.50

Current Ratio1.96

Quick Ratio1.52

Revenue 5Y1.17%

FCF 5Y6.36%

Target$168.75

Target Upside11.87%

Target Median$173.50

Target Range150.00 - 185.00

Volume3.20M

Avg Volume2.28M

EPS Surprise0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

82/100

Fortaleza financiera

Deuda, caja, estabilidad

92/100

Potencial de crecimiento

Ingresos y expansión

44/100

Atractivo del precio

Barata o cara hoy

42/100

Por qué este puntaje▼

Márgenes estables o en mejora · 18.8%Flujo de caja libre positivo · 4.07Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.5Liquidez saludable · 1.96

Analyst view

Analyst sentiment and price target

Analyst sentiment

Based on 41 analyst votes · 2026-09-05

89/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-28

Bajo

$150.00

Promedio

$170.00

Mediana

$175.00

Alto

$185.00

Resumen de la compañía

IPO: 11/18/1999

Industria: Medical - Diagnostics & Research

P/B i: 5.80

Deuda / Patrimonio i: 0.50

Margen operativo: 21.29%

Margen neto: 18.75%

ROE i: -

ROIC: -

Salud financiera

Puntaje18 / 20

Deuda / Patrimonio: 0.50

Ratio corriente: 1.96

Ratio rápido: 1.52

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

KIRKWOOD JONAH PREVOST

Transacción: 06/26/2026

VENTA

Cambio

-30

Precio

$136.01

Presentación

06/29/2026

Tipo

VENTA

MCDONNELL PADRAIG

Transacción: 06/03/2026

VENTA

Cambio

-418

Precio

$137.40

Presentación

06/05/2026

Tipo

VENTA

Downs Timothy Charles

Transacción: 06/02/2026

OTRO

Cambio

Precio

Not reported

Presentación

06/05/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
KIRKWOOD JONAH PREVOST	VENTA	-30	$136.01	06/26/2026	06/29/2026
MCDONNELL PADRAIG	VENTA	-418	$137.40	06/03/2026	06/05/2026
Downs Timothy Charles	OTRO	0	Not reported	06/02/2026	06/05/2026
Dolsten Mikael	VENTA	-1,600	$135.42	05/29/2026	06/02/2026
Buckner Michael Steven	COMPRA	+8,872	Not reported	05/19/2026	05/21/2026
MAY SIMON	VENTA	-368	$115.62	05/08/2026	05/12/2026
Buckner Michael Steven	OTRO	0	Not reported	05/04/2026	05/08/2026
Henson Meghan	VENTA	-153	$113.98	03/31/2026	04/02/2026
Anand Mala	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
Brown Judy L	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
Dolsten Mikael	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
KOH BOON HWEE	VENTA	-648	$111.75	03/19/2026	03/23/2026
Podolsky Daniel K	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
WILSON DOW R	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
Soriot Pascal	VENTA	-648	$111.75	03/19/2026	03/23/2026
SCANGOS GEORGE A	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
BRAWLEY OTIS W	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
Rataj Sue H.	COMPRA	+2,158	$111.75	03/19/2026	03/23/2026
KIRKWOOD JONAH PREVOST	VENTA	-124	$121.38	02/27/2026	03/03/2026
MCDONNELL PADRAIG	VENTA	-279	$121.38	02/27/2026	03/03/2026

Sobre la compañía

Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Fuente - Link

Competidores

ALC BDX CAH EW HLN INSM IQV MTD RMD WAT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent's ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency.

Business Wire

Agilent Introduces the Cary 635 FTIR Spectrometer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the Agilent Cary 635 FTIR spectrometer, setting a new standard for compact, high-performance Fourier transform infrared (FTIR) analysis. Combining robust engineering, superior performance, and intuitive usability, the Cary 635 FTIR provides laboratories with a powerful solution that enhances reliability, boosts productivity, and delivers the versatility required for today's analytical challe.

Business Wire

INTURAI VENTURES COMPLETES DOMECOMMAND ACQUISITION

INTURAI VENTURES COMPLETES DOMECOMMAND ACQUISITION PR Newswire VANCOUVER, BC, Sept. 1, 2026

GuruFocus

International Markets and Agilent (A): A Deep Dive for Investors

Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Zacks Investment Research

Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance

Agilent Technologies is upgraded to Buy after a strong Q3 2026, with revenue up 8% and EPS up 18% YoY. All three segments posted robust growth, notably Life Sciences and Diagnostics, which saw operating margin jump nearly 600 bps to 23.5%. Guidance for Q4 and FY26 implies continued momentum, with management projecting 6.5–7.5% revenue growth and 8.5% EPS growth for Q4.

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-27	1.41	1.49	0.08
2026-02-25	1.37	1.36	-0.01
2025-11-24	1.58431	1.59	0.00569
2025-08-27	1.37	1.37	0
2025-05-28	1.26	1.31	0.05
2025-02-26	1.28	1.31	0.03
2024-11-25	1.41	1.46	0.05
2024-08-21	1.26	1.32	0.06
2024-05-29	1.19	1.22	0.03
2024-02-27	1.22	1.29	0.07
2023-11-20	1.34	1.38	0.04
2023-08-15	1.37	1.43	0.06